Novartis asks FDA for Galvus review extension
Novartis has asked the FDA to extend the review period for its highly anticipated developmental diabetes drug Galvus by three ...
Your Email Address: *
Recipient(s) Email Address: *
(Separate multiple e-mail addresses with commas. Limited to 20 addresses.)
The e-mail address(es) that you supply to use this service will only be used to send the requested article.